Initiation rates of statin therapy for the primary prevention of cardiovascular disease: An assessment of differences between countries of the UK and between regions within England

BMJ Open

Volumn 5, Issue 3, 2015, Pages

  O'Keeffe, Aidan G ^a   Petersen, Irene ^a   Nazareth, Irwin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; FEMALE; GENDER; GEOGRAPHIC DISTRIBUTION; HUMAN; MALE; MIDDLE AGED; SOCIAL ISOLATION; UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT; CARDIOVASCULAR DISEASES; ENGLAND; NORTHERN IRELAND; PRESCRIPTION; PRIMARY HEALTH CARE; PRIMARY PREVENTION; SCOTLAND; STATISTICS AND NUMERICAL DATA; WALES;

ADULT; CARDIOVASCULAR DISEASES; DRUG PRESCRIPTIONS; ENGLAND; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NORTHERN IRELAND; PRIMARY HEALTH CARE; PRIMARY PREVENTION; SCOTLAND; WALES;

EID: 84926500115     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-007207     Document Type: Article

References (34)

1. Baigent C, Keech A, Kearney PM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
2. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 1976;29:1346-8.
3. Endo A. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J Antibiot (Tokyo) 1979;32:852-4.
4. Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother 2004;5:2583-96.
5. [No authors listed] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-8.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
8. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
9. Trusler D. Statin prescriptions in UK now total a million each week. BMJ 2011;343:d4350.
10. NICE: Developed by the National Collaborating Centre for Primary Care, Clinic. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardivascular diseases. NICE Clinical Guideline 67; 2008.
11. Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998;317:1134-5.
12. Packham C, Pearson J, Robinson J, et al. Use of statins in general practices, 1996-8: cross sectional study. BMJ 2000;320:1583-4.
13. Majeed A, Moser K, Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health 2000;22:275-9.
14. DeWilde S, Carey IM, Bremner SA, et al. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart Br Card Soc 2003;89:417-21.
15. Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005;330:821.
16. Carey IM, DeWilde S, Shah SM, et al. Statin use after first myocardial infarction in UK men and women from 1997 to 2006:Who started and who continued treatment? Nutr Metab Cardiovasc Dis NMCD 2012;22:400-8.
17. Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. Br J Clin Pharmacol 2005;59:227-32.
18. Walley T, Folino-Gallo P, Stephens P, et al. Trends in prescribing and utilization of statins and other lipid lowering drugs cross Europe 1997-2003. Br J Clin Pharmacol 2005;60:543-51.
19. Bartholomeeusen S, Vandenbroucke JP, Truyers C, et al. Trends in total cholesterol screening and in prescribing lipid-lowering drugs in general practice in the period 1994-2003. BMC Fam Pract 2008;9:39.
20. Ma J, Sehgal NL, Ayanian JZ, et al. National trends in statin use by coronary heart disease risk category. PLoS Med 2005;2: e123.
21. Ashworth M, Lloyd D, Smith RS, et al. Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. J Public Health Oxf Engl 2007;29:40-7.
22. Lis Y, Mann RD. The VAMP research multi-purpose database in the U.K. J Clin Epidemiol 1995;48:431-43.
23. Blak BT, Thompson M, Dattani H, et al. Generalisability of the health improvement network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251-5.
24. Man S-L, Petersen I, Thompson M, et al. Antiepileptic drugs during pregnancy in primary care: a UK Population Based Study. PLoS ONE 2012;7:e52339.
25. Petersen I, McCrea RL, Osborn DJP, et al. Discontinuation of antipsychotic medication in pregnancy: a cohort study. Schizophr Res 2014;159:218-25.
26. Marston L, Nazareth I, Petersen I, et al. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 2014;4:e006135.
27. Wang Y, Hunt K, Nazareth I, et al. Do men consult less than women? An analysis of routinely collected UK general practice data. BMJ Open 2013;3:e003320.
28. British Heart Foundation Health Promotion Research Group, Department of Public Health, University of Oxford. Coronary heart disease statistics: a compendium of health statistics [Internet]. 2012. http://www.bhf.org.uk/publications/view-publication.aspx?ps=1002097
29. Gibson A, Asthana S, Brigham P, et al. Geographies of need and the new NHS: methodological issues in the definition and measurement of the health needs of local populations. Health Place 2002;8:47-60.
30. Ward P, Noyce P, St L. Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England. J Epidemiol Community Health 2004;58:89-96.
31. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984;76:4-12.
32. Packham C, Robinson J, Morris J, et al . Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med 1999;21:60-4.
33. Marston L, Carpenter JR, Walters KR, et al. Issues in multiple imputation of missing data for large general practice clinical databases. Pharmacoepidemiol Drug Saf 2010;19:618-26.
34. Marston L, Carpenter JR, Walters KR, et al. Smoker, ex-smoker or non-smoker? The validity of routinely recorded smoking status in UK primary care: a cross-sectional study. BMJ Open 2014;4:e004958.